Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 242 matching drugs for HSPA5 — including drugs targeting any of its 133 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin HSPA5 Direct 1
disulfiram, copper, alkylating agents HSPA5 Direct 1
adagrasib KRAS SSL via KRAS yes 2
afatinib EGFR SSL via EGFR yes 2
dacomitinib EGFR SSL via EGFR yes 2
erlotinib EGFR SSL via EGFR yes 2
gefitinib EGFR SSL via EGFR yes 2
sotorasib KRAS SSL via KRAS yes 2
lazertinib and amivantamab EGFR SSL via EGFR 1
osimertinib EGFR SSL via EGFR yes 1
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab NTRK1 SSL via NTRK1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) NTRK1 SSL via NTRK1 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FYN SSL via FYN 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib MAP2K1 SSL via MAP2K1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib NTRK1 SSL via NTRK1 3
dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, pharmacological study, sirolimus MTOR SSL via MTOR 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib YES1 SSL via YES1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel MAP2K1 SSL via MAP2K1 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment FYN SSL via FYN 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib MAP2K1 SSL via MAP2K1 2
cft1946, trametinib, cetuximab MAP2K1 SSL via MAP2K1 2
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study MTOR SSL via MTOR 2
cobimetinib, mehd7945a MAP2K1 SSL via MAP2K1 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib NTRK1 SSL via NTRK1 2
everolimus MTOR SSL via MTOR yes 2
jab-3312, binimetinib, pembrolizumab, sotorasib, osimertinib MAP2K1 SSL via MAP2K1 2
ksq-001ex, interleukin-2, cyclophosphamide, fludarabine POLA1 SSL via POLA1 2
mirdametinib, bgb-3245 MAP2K1 SSL via MAP2K1 2
nivolumab, ipilimumab, cobimetinib MAP2K1 SSL via MAP2K1 2
regorafenib NTRK1 SSL via NTRK1 2
regorafenib, laboratory biomarker analysis NTRK1 SSL via NTRK1 2
selumetinib, medi4736, tremelimumab MAP2K1 SSL via MAP2K1 2
temsirolimus MTOR SSL via MTOR 2
temsirolimus, laboratory biomarker analysis MTOR SSL via MTOR 2
5-fluorouracil (5-fu), leucovorin, oxaliplatin, atezolizumab, cobimetinib, ramucirumab, paclitaxel, pegylated recombinant human hyaluronidase (pegph20), bl-8040, linagliptin, atezolizumab, cobimetinib, cisplatin, tiragolumab, 5-fluorouracil (5-fu) MAP2K1 SSL via MAP2K1 1
aee788, everolimus MTOR SSL via MTOR 1
afatinib, dasatinib, palbociclib, everolimus, olaparib FYN SSL via FYN 1
afatinib, dasatinib, palbociclib, everolimus, olaparib MTOR SSL via MTOR 1
afatinib, dasatinib, palbociclib, everolimus, olaparib YES1 SSL via YES1 1
akt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib MAP2K1 SSL via MAP2K1 1
aldesleukin, biopsy, biospecimen collection, computed tomography, cyclophosphamide, excisional biopsy, fludarabine, magnetic resonance imaging, standard treatment, therapeutic tumor infiltrating lymphocytes POLA1 SSL via POLA1 1
alisertib AURKA SSL via AURKA 1
alisertib, gemcitabine AURKA SSL via AURKA 1
alpelisib, everolimus, exemestane MTOR SSL via MTOR 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib MTOR SSL via MTOR 1
autologous mesothelin-specific tcr-t cells, cyclophosphamide, fludarabine, bendamustine POLA1 SSL via POLA1 1
azd6244, dacarbazine, erlotinib, docetaxel, temsirolimus MTOR SSL via MTOR 1
bendamustine, biopsy, biospecimen collection, computed tomography, cyclophosphamide, echocardiography, fludarabine, leukapheresis, magnetic resonance imaging, multigated acquisition scan, positron emission tomography, t-cell receptor-engineered t-cells POLA1 SSL via POLA1 1
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment YES1 SSL via YES1 1
bevacizumab, dasatinib, placebo FYN SSL via FYN 1
bevacizumab, dasatinib, placebo YES1 SSL via YES1 1
bevacizumab, everolimus, octreotide acetate MTOR SSL via MTOR 1
bevacizumab, temsirolimus MTOR SSL via MTOR 1
binimetinib MAP2K1 SSL via MAP2K1 yes 1
binimetinib, hydroxychloroquine MAP2K1 SSL via MAP2K1 1
biopsy, biospecimen collection, computed tomography, larotrectinib, magnetic resonance imaging NTRK1 SSL via NTRK1 1
biopsy, calaspargase pegol-mknl, cobimetinib MAP2K1 SSL via MAP2K1 1
bosutinib MAP2K1 SSL via MAP2K1 1
busulfan, anti-thymocyte globulin, fludarabine, cyclosporine, mycophenolate mofetil POLA1 SSL via POLA1 1
chemotherapy, cladribine, radiation therapy POLA1 SSL via POLA1 1
cobimetinib, hydroxychloroquine, atezolizumab MAP2K1 SSL via MAP2K1 1
cobimetinib, olaparib, onvansertib, azenosertib, saruparib, tremelimumab MAP2K1 SSL via MAP2K1 1
conventional surgery, laboratory biomarker analysis, sorafenib tosylate, temsirolimus MTOR SSL via MTOR 1
cyclophosphamide, fludarabine, aldesleukin, anti-hcd70 car transduced pbl POLA1 SSL via POLA1 1
cyclophosphamide, fludarabine, mutant kras g12v-specific tcr transduced autologous t cells, anti-pd-1 monoclonal antibody POLA1 SSL via POLA1 1
cytoreductive surgery, perifosine, temsirolimus MTOR SSL via MTOR 1
dabrafenib, trametinib MAP2K1 SSL via MAP2K1 1
dabrafenib, trametinib, carboplatin, vincristine MAP2K1 SSL via MAP2K1 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride FYN SSL via FYN 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride YES1 SSL via YES1 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method FYN SSL via FYN 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method YES1 SSL via YES1 1
dasatinib, laboratory biomarker analysis, physiologic testing FYN SSL via FYN 1
dasatinib, laboratory biomarker analysis, physiologic testing YES1 SSL via YES1 1
dasatinib, mfolfox6 FYN SSL via FYN 1
dasatinib, mfolfox6 YES1 SSL via YES1 1
dasatinib, pharmacological study FYN SSL via FYN 1
dasatinib, pharmacological study YES1 SSL via YES1 1
dasatinib, temozolomide, placebo, radiation therapy FYN SSL via FYN 1
dasatinib, temozolomide, placebo, radiation therapy YES1 SSL via YES1 1
disulfiram, copper, alkylating agents CALR SSL via CALR 1
disulfiram, copper, alkylating agents HSP90B1 SSL via HSP90B1 1
disulfiram, copper, alkylating agents PRDX1 SSL via PRDX1 1
e7 tcr cells, aldesleukin, fludarabine, cyclophosphamide POLA1 SSL via POLA1 1
entrectinib NTRK1 SSL via NTRK1 yes 1
enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) AURKA SSL via AURKA 1
enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) AURKB SSL via AURKB 1
enzastaurin, lomustine AURKA SSL via AURKA 1
enzastaurin, lomustine AURKB SSL via AURKB 1
enzastaurin, temozolomide, radiation therapy AURKA SSL via AURKA 1
enzastaurin, temozolomide, radiation therapy AURKB SSL via AURKB 1
epidermal growth factor receptor(egfrv)iii chimeric antigen receptor (car) transduced pbl, aldesleukin, fludarabine, cyclophosphamide POLA1 SSL via POLA1 1
erlotinib hydrochloride, selumetinib, laboratory biomarker analysis MAP2K1 SSL via MAP2K1 1
erlotinib, temsirolimus, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study MTOR SSL via MTOR 1
everolimus, archival tissue analysis MTOR SSL via MTOR 1
everolimus, gefitinib MTOR SSL via MTOR 1
everolimus, laboratory biomarker analysis MTOR SSL via MTOR 1
everolimus, lde 225 MTOR SSL via MTOR 1
everolimus, placebo MTOR SSL via MTOR 1
everolimus, sorafenib MTOR SSL via MTOR 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.